DNA sequencing costs are dropping exponentially, and DNA synthesis costs are not far behind.
These technologies are enabling genome sequencing and engineering at an unprecedented scale. Many of the world's most important drugs are derived from nature, found piecemeal without knowledge of the source DNA sequence. Hexagon Bio's mission is to turn the world's DNA into medicines.
Our core technologies were developed by our founders at Stanford University. Hexagon Bio's proprietary methods allow us to develop drugs against novel targets, even targets previously considered undruggable. Our focus is on oncology and antifungal drugs.
The TICker algorithm can identify human targets of cryptic natural products, prioritizing among thousands of candidates.
The HEx platform for rapid production of Targeted Bioengineered Small Molecules (TBSMs) creates new chemical entities based on truly novel chemical scaffolds.
Colin J. B. Harvey, Mancheng Tang, Ulrich Schlecht, Joe Horecka, Curt R. Fischer, Hsiao-Ching Lin, Jian Li, Brian Naughton, James Cherry, Molly Miranda, Yong Fuga Li, Angela M. Chu, James R. Hennessy, Gergana A. Vandova, Diane Inglis, Raeka S. Aiyar, Lars M. Steinmetz, Ronald W. Davis, Marnix H. Medema, Elizabeth Sattely, Chaitan Khosla, Robert P. St. Onge, Yi Tang, and Maureen E. Hillenmeyer.
We have ongoing collaborations with academic, governmental and industrial entities for genome sequencing projects.
Do you have fungal strains that you would like to have sequenced? We are looking to work with you! If you are interested in partnering with us, please get in touch.